Abstract
The aim of this prospective sequential multinational (5 countries) study was to concurrently evaluate the effects of subcutaneous sumatriptan on clinical parameters. health-related quality-of-Iife (HRQOL) measures. workplace productivity and patient satisfaction. This report presents the HRQOL results.
582 patients (aged 18 to 65 years) with moderate to severe migraine received their customary anti migraine therapy for 12 weeks and then subcutaneous sumatriptan for 24 weeks. The Short Form-36 Health Survey and the MigraineSpecitic Quality of Life Questionnaire were completed at a screening visit (baseline). at the end of the 12-week customary therapy phase. and at 12 and 24 weeks of the sumatriptan phase.
Scores for most of the Short Form-36 dimensions improved significantly (p < 0.(5) after 12 and 24 weeks of sumatriptan therapy compared with 12 weeks of customary therapy. in each country. Similarly. scores on all Migraine-Specific Quality of Life Questionnaire dimensions were signiticantly (p < 0.05: paired t-test) improved after 12 weeks (in all countries) and 24 weeks (in 4 of5 countries) of sumatriptan therapy compared with 12 weeks of customary therapy.
This study demonstrates that. in 5 countries. treatment of migraine attacks with subcutaneous sumatriptan compared with customary therapy was associated with improvements in HRQOL. as measured by both general health status and diseasespecific instruments.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dahlöf C. Assessment of health-related quality of life in migraine. Cephalalgia 1993; 13: 233–7
Kongpatanakul S. Strum RI Quality of life, health status, and clinical drug research. Pharmaco Economics 1992; 2: 8–14
The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316–21
Cady RK, Wendt JK. Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265:2831–5
The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan–an oral dose-defining study. Eur Neurol 1991; 31: 300–5
The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oralsumatriptan for the acute treatment of migraine. Eur Neurol1991; 31: 306–13
Mushet GR, Miller O, Clements B, et al. Impact of sumatriptan on workplace productivity. nonwork activities. and health-re-lated quality of life among hospital employees with migraine.Headache 1996; 36: 137–43
Cohen JA. Beall DG. Miller OW, et al. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic.and clinical consequences. Fam Med 1996; 28: 171–7
Heywood J. Bouchard J. Cortelli P. et al. A multinational investigation of the impact of subcutaneous sumatriptan. I: design.methods and clinical findings. Pharmaco Economics 1997; 11 Suppl.1: 11–23
Cortelli P. Dahlöf C. Bouchard J. et al. A multinational investigation of the impact of subcutaneous sumatriptan. III: workplaceproductivity and nonworkplace activity. Pharmaco Economics1997; 11 Suppl. 1: 35–42
Bouchard J. Cortelli P. Dahlof C. et al. A multinational investigation of the impact of subcutaneous sumatriptan. IV: patientsatisfaction. Pharmaco Economics 1997; 11 Suppl. 1: 43–50
Headache Classification Committee of the International Headache Society Classification and diagnostic criteria for headachedisorders. cranial neuralgias and facial pain. Cephalalgia 1988; 8: 1–96
Ware Jr JE. SF-36 Health Survey Manual and Interpretalion Guide. Boston: The Health Institute. New England Medical Center Hospitals, Inc., 1993
Ware Jr JE, Sherbourne CD. The MOS 36-ltem Short-Form Health Survey (SF-36). I. Conceptual framework and itemselection. Med Care 1992; 30: 473–83
Miller OW, Kirchdoerfer LJ, Shepherd MD, et al. A diseasespecific instrument 10 measure quality of life effects altributableto migraine. Poster presentation at the HealthServices Research Association 10th Annual Meeting: 1993June 27-29: Washington.
Reese PRO Joseph AJ. Quality translations–no substitute for psychometric evaluation lposterl. 2nd Meeting of the InternationalSociety for Quality of Life Research: 1995 Oct14-17; Montreal
Solomon GO. Skobieranda FG. Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan.Headache 1995; 35: 449–54
Solomon GD. Nielsen K. Miller W. The effetcs of sumatripan on migraine: health-related quality of life. Med Interface(June); 134–41
Dahlof C. Edwards C, Toth L. Sumatriptan injection is superior to placebo in the acute treatment of migraine–with regard toboth efficacy and general well-heing. Cephalalgia 1992; 12:214–20
De Lissovoy G. Lazarus SS. The economic cost of migraine: present state of knowledge. Neurology 1994; 44 Suppl. 4:56–62
Lipton TB. Stewart WF. Health-related quality of life in headache research. Headache 1995; 35: 447–8
Author information
Authors and Affiliations
Additional information
Correspondence and reprints: Kim L. Price, Glaxo Wellcome Research and Development, Pharmacoeconomic Research, Greenford Road, Greenford, Middlesex UB6 OHE, England.
On behalf of the Value of Sumatriptan Study Group
Rights and permissions
About this article
Cite this article
Dahlöf, C., Bouchard, J., Cortelli, P. et al. A Multinational Investigation of the Impact of Subcutaneous Sumatriptan. Pharmaco economics 11 (Suppl 1), 24–34 (1997). https://doi.org/10.2165/00019053-199700111-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199700111-00005